Development and multi‐institutional validation of an upgrading risk tool for Gleason 6 prostate cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|119|22|3992-4002

ISSN： 0008-543x

Source： CANCER, Vol.119, Iss.22, 2013-11, pp. : 3992-4002

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Erratum: TruongM, SlezakJA, LinCP, IremashviliV, SadoM, RazmariaAA, LeversonG, SolowayMS, EggenerSE, AbelEJ, DownsTM, and JarrardDF. Development and multi‐institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer. 2013;119:3992–4002.

By  

CANCER, Vol. 120, Iss. 5, 2014-03 ,pp. : 769-769

John Wiley & Sons Inc

Access to resources Recommend Favorite

Gleason Score 6 - Prostate Cancer or Benign Variant?

By  

Oncology Research and Treatment, Vol. 38, Iss. 12, 2015-0 ,pp. : 629-632

Karger

Access to resources Recommend Favorite

Low-Risk Prostate Cancer and Tumor Upgrading in the Surgical Specimen: Analysis of Clinical Factors Predicting Tumor Upgrading in a Contemporary Series of Patients Who were Evaluated According to the Modified Gleason Score Grading System

By  

Current Urology, Vol. 10, Iss. 3, 2017-07 ,pp. : 118-125

Karger

Access to resources Recommend Favorite

Low-Risk Prostate Cancer and Tumor Upgrading to Higher Patterns in the Surgical Specimen. Analysis of Clinical Factors Predicting Tumor Upgrading to Higher Gleason Patterns in a Contemporary Series of Patients Who Have Been Evaluated According to the Modified Gleason Score Grading System

By  

Urologia Internationalis, Vol. 97, Iss. 1, 2016-03 ,pp. : 32-41

Karger

Access to resources Recommend Favorite

The Modulating Effects of Benign Prostate Enlargement Medications on Upgrading Predictors in Patients with Gleason 6 at Biopsy

By  

Current Urology, Vol. 10, Iss. 2, 2017-05 ,pp. : 97-104

Karger

Access to resources Recommend Favorite